Occam Places Biotech Leader David Southwell as Chairman of Revolo Biotherapeutics
In January 2024, Occam recruited serial biotech CEO David Southwell as Chairman of Revolo Biotherapeutics, a Morningside investment with a novel platform addressing autoimmune disorders.
David is an experienced financial executive who earlier in his career worked in numerous private and public companies and executed multiple IPOs. He subsequently migrated to operational leadership roles with small biotechs and larger commercial-stage companies.
Most recently, David served as CEO of TScan Therapeutics, Inc. (NASDAQ: TCRX), a clinical-stage immuno-oncology company focused on T cell receptors. Prior to that, he was the CEO of Inotek Pharmaceuticals (NASDAQ: ITEK), a clinical-stage ophthalmology company that merged with Rocket Pharmaceuticals in 2018. David also served as the EVP and CFO of Human Genome Sciences until that company was acquired by GSK in 2012, and then as EVP and CFO of Sepracor. His career began in investment banking at Lehman Brothers Inc.
Occam Global is an executive recruiting and leadership advisory firm with specialties across technological fields including Biotech, TechBio, AI-ML, Cell/Gene Therapy, Diagnostics/Genomics, Medical Devices, Research Tools, Digital Health, Alternative Energy, AgTech, EdTech, Robotics as well as adjacencies within Venture Capital and Private Equity. Occam helps build leadership teams that meet the demands of the rapidly developing, competitive, and challenging industries it serves. Occam Global recruits leading C-Suite executives and board members for the most exciting and innovative clients across the world with a specific focus on the UK, Continental Europe, the US, and Asia.